{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:05:46Z","timestamp":1794737146137,"version":"4.9.1"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Urothelial carcinoma (UC) is a common malignancy with significant associated mortality. Recent clinical trials suggest an emerging role for HER2-targeted therapy. Testing for HER2 expression in UC is not part of current routine clinical practice. In consequence, the prevalence of HER2 expression in UC is not well defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature review (SLR) was conducted to characterize HER2 expression in both locally advanced unresectable or metastatic (LA\/mUC) and earlier stage UC, classified as HER2+, HER2-low, HER2-. HER2+ was defined as an immunohistochemistry (IHC) score of 3+ or IHC 2+ and ISH\/FISH+. HER2-low was defined as an IHC score of 2+ and ISH\/FISH- or IHC 1+. HER2- was defined as an IHC score of 0. Weighted averages were calculated to generate an estimate of the population prevalence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 88 studies were identified, with 45, 30, and 13 studies investigating LA\/mUC, earlier stage UC, and mixed stage\/unspecified, respectively. The most common assays used were Dako HercepTest and Ventana Pathway anti-HER2\/neu (4B5) for IHC to assess HER2 protein expression; Abbott PathVysion HER-2 DNA Probe Kit, FoundationOne CDx, and Guardant360 CDx for assessing HER2 gene amplification. The most frequently cited scoring guidelines were ASCO\/CAP guidelines for breast cancer and gastric cancer, though most studies defined their own criteria for HER2 expression. Using the pre-specified definition, HER2+ prevalence ranged from 6.7% to 37.5% with a weighted average of 13.0% in LA\/mUC. Only 1 study presented data that could be classified as HER2+ based on pre-specified criteria in earlier stage UC patients, and this study represented a likely outlier, at 76.0%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results from this SLR help to shed light on HER2 expression in UC, a potentially clinically relevant biomarker-driven subpopulation for emerging HER2-directed regimens. Results of this SLR illuminate the variability in how HER2+ status expression levels are being assessed and how HER2+ is defined. Consensus on standardized HER2 testing and scoring criteria is paramount to better understand the clinical relevance in patients with UC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1011885","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T07:21:07Z","timestamp":1666336867000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["HER2 expression in urothelial carcinoma, a systematic literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Emilie","family":"Scherrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Bloudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"B1","unstructured":"Cancer today2021"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.008","article-title":"A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens","volume":"63","author":"Hansel","year":"2013","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.028","article-title":"Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5","volume":"51","author":"Marcos-Gragera","year":"2015","journal-title":"Eur J Cancer"},{"key":"B4","unstructured":"SEER cancer stat facts: Bladder cancer2021"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.seminoncol.2012.08.007","article-title":"New therapeutic challenges in advanced bladder cancer","volume":"39","author":"Bellmunt","year":"2012","journal-title":"Semin Oncol"},{"key":"B7","unstructured":"Bladder cancer (Version 4.2021)2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5682078","DOI":"10.1155\/2018\/5682078","article-title":"Update on the treatment of metastatic urothelial carcinoma","author":"Bukhari","year":"2018","journal-title":"ScientificWorldJournal"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20285","article-title":"Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis","volume":"27","author":"Hepp","year":"2021","journal-title":"J Manage Care Spec Pharm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0072","article-title":"NCCN guidelines insights: Bladder cancer, version 5.2018","volume":"16","author":"Flaig","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","unstructured":"eUpdate: bladder cancer treatment recommendations2020"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis","volume":"104","author":"Martini","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"B17","volume-title":"(enfortumab vedotin-ejfv) [prescribing information]","year":"2022"},{"key":"B18","volume-title":"(sacituzumab govitecan-hziy) [prescribing information]","year":"2022"},{"key":"B19","volume-title":"(erdafitinib) [prescribing information]","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10731","article-title":"HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications","volume":"102","author":"Kr\u00fcger","year":"2002","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.432","article-title":"HER2 as a target in invasive urothelial carcinoma","volume":"4","author":"Bellmunt","year":"2015","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"B23","article-title":"Urothelial carcinomas: a focus on human epidermal receptors signaling","volume":"3","author":"Grivas","year":"2011","journal-title":"Am J Transl Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.10.040","article-title":"HER-2\/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder","volume":"63","author":"Coogan","year":"2004","journal-title":"Urology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2003.08.027","article-title":"HER2\/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy","volume":"40","author":"Latif","year":"2004","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/02841860260088836","article-title":"HER-2\u2013a possible target for therapy of metastatic urinary bladder carcinoma","volume":"41","author":"Wester","year":"2002","journal-title":"Acta Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE","volume":"125","author":"Perez","year":"2019","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: A review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.11.006","article-title":"The evolving landscape of antibody-drug conjugates for urothelial carcinoma","volume":"19","author":"Abel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1309\/41VLTFX3YPP1HF6F","article-title":"HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases","volume":"130","author":"Hansel","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the college of American pathologists, American society for clinical pathology, and American society of clinical oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.07.014","article-title":"Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases","volume":"57","author":"Goodman","year":"2016","journal-title":"Hum Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2014-0015","article-title":"EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression","volume":"49","author":"Carlsson","year":"2015","journal-title":"On possibility to target these receptors radionuclides Radiol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05452.x","article-title":"Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases","volume":"95","author":"G\u00e5rdmark","year":"2005","journal-title":"BJU Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24337","article-title":"A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma","volume":"115","author":"W\u00fclfing","year":"2009","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11903","article-title":"Critical overview of HER2 assessement in bladder cancer: What is missing for a better therapeutic approach","volume":"37","author":"Cimpean","year":"2017","journal-title":"Anticancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.humpath.2020.10.006","article-title":"Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Grigg","year":"2021","journal-title":"Hum Pathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.01.017","article-title":"Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study","volume":"61","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-004-0986-4","article-title":"Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2\/ neu (c-erbb-2) status in urothelial carcinoma","volume":"444","author":"de Pinieux","year":"2004","journal-title":"Virchows Arch"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1200\/JCO.2021.39.15_suppl.4534","article-title":"RC48-ADC combined with toripalimab,\u200b an anti-PD-1 monoclonal antibody (Ab),\u200b in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib\/II study.2021 ASCO annual meeting; 2021 jun 4-8; Chicago, IL, USA","volume":"30","author":"Zhou","year":"2021","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clgc.2014.08.002","article-title":"Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy","volume":"13","author":"Necchi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1871-x","article-title":"HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.173164","article-title":"Human epidermal growth factor receptor 2\/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype","volume":"4","author":"Kumar","year":"2015","journal-title":"South Asian J Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10808","article-title":"Does HER2\/neu expression provide prognostic information in patients with advanced urothelial carcinoma","volume":"95","author":"Gandour-Edwards","year":"2002","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"731.e1","DOI":"10.1016\/j.urolonc.2020.12.021","article-title":"Comprehensive genomic profiling of histologic subtypes of urethral carcinomas","volume":"39","author":"Jacob","year":"2021","journal-title":"Urol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24188","article-title":"Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers","volume":"9","author":"Cabel","year":"2018","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","first-page":"S718","DOI":"10.1016\/j.annonc.2021.08.107","article-title":"Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I\/II trials. ESMO congress","volume":"2021","author":"Pobel","year":"2021","journal-title":"Virtual Ann Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod Pathol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1541-7786.MCR-20-0751","article-title":"Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes","volume":"19","author":"Alhalabi","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1200\/JCO.2019.37.7_suppl.407","article-title":"Characterization of actionable genomic alterations to guide targeted therapy for metastatic urothelial carcinoma. 2019 ASCO genitourinary cancers symposium; 2019 Feb 14-19; San Francisco, CA, USA","volume":"37","author":"Almassi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15006","article-title":"Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions","volume":"125","author":"Madison","year":"2020","journal-title":"BJU Int"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31314","article-title":"Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA","volume":"124","author":"Agarwal","year":"2018","journal-title":"Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"B69","first-page":"V377","article-title":"Genomic analysis of urothelial cancer and associations with treatment choice and outcome","volume-title":"Ann. oncol","author":"Sarid","year":"2019"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.07.010","article-title":"Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin","volume":"13","author":"Millis","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/JCO.2019.37.7_suppl.401","article-title":"Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC). 2019 ASCO genitourinary cancers symposium; 2019 Feb 14-19; San Francisco, CA, USA","volume":"37","author":"Villamar","year":"2019","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/BLC-160069","article-title":"Clinical significance of early changes in circulating tumor cells from patients receiving first-line cisplatin-based chemotherapy for metastatic urothelial carcinoma","volume":"2","author":"Fina","year":"2016","journal-title":"Bladder Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601245","article-title":"HER2\/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder","volume":"89","author":"Latif","year":"2003","journal-title":"Br J Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.30699\/IJP.2020.130859.2447","article-title":"Survivin and Her2 expressions in different grades of urothelial neoplasms of urinary bladder","volume":"16","author":"Moradi Tabriz","year":"2021","journal-title":"Iran J Pathol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.09.047","article-title":"Expression of the epidermal growth factor receptor and her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the radiation therapy oncology group","volume":"62","author":"Chakravarti","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B77","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09190.x","article-title":"Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder","volume":"106","author":"Bolenz","year":"2010","journal-title":"BJU Int"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/srep42713","article-title":"Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy","volume":"7","author":"Kiss","year":"2017","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.127033","article-title":"Status of Her2 over expression in muscle invasive urothelial bladder carcinoma: Report of 21 cases","volume":"6","author":"Mejri","year":"2014","journal-title":"Urol Ann"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16554","article-title":"HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts","volume":"8","author":"Eriksson","year":"2017","journal-title":"Oncotarget"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000798","article-title":"Potential of molecular targeted therapy of HER-2 and cox-2 for invasive transitional cell carcinoma of the urinary bladder","volume":"23","author":"Naruse","year":"2010","journal-title":"Oncol Rep"},{"key":"B84","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1200\/JCO.2021.39.6_suppl.477","article-title":"Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar immune microenvironment as compared to conventional UC","author":"Kossai","year":"2021","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111954","article-title":"Nuclear factor-\u03baB overexpression is correlated with poor outcomes after multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer","volume":"8","author":"Chiang","year":"2019","journal-title":"J Clin Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"533.e1","DOI":"10.1016\/j.urolonc.2016.07.006","article-title":"The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer","volume":"34","author":"Soria","year":"2016","journal-title":"Urol Oncol"},{"key":"B87","first-page":"57","article-title":"Potential for HER-2\/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescentin situ hybridization","volume":"19","author":"Matsubara","year":"2008","journal-title":"Oncol Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.07.011","article-title":"Histological variants of urothelial carcinoma predict no response to neoadjuvant chemotherapy","volume":"20","author":"Leite","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05497.x","article-title":"Expression of the epidermal growth factor receptor family in normal and malignant urothelium","volume":"95","author":"R\u00f8tterud","year":"2005","journal-title":"BJU Int"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-007-9283-x","article-title":"Prognostic significance of Her2\/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy","volume":"40","author":"Kolla","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0000556759.93252.81","article-title":"Characterizing the landscape of actionable genomic alterations to identify opportunities for targeted therapy trials in patients with localized bladder cancer. American urological association\u2019s 2019 annual meeting; 2019 may 3-6; Chicago, IL, USA","volume":"201","author":"Almassi","year":"2019","journal-title":"J Urol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12885-016-2703-5","article-title":"Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques","volume":"16","author":"Nedjadi","year":"2016","journal-title":"BMC Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","article-title":"Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.653491","article-title":"The clinical significance and prognostic value of HER2 expression in bladder cancer: A meta-analysis and a bioinformatic analysis","volume":"11","author":"Gan","year":"2021","journal-title":"Front Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2022.40.6_suppl.556","article-title":"Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts). 2022 ASCO genitourinary cancers symposium; 2022 Feb 17-19; San Francisco, CA, USA","volume":"40","author":"Lattanzi","year":"2022","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02541-9","article-title":"HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany","volume":"474","author":"Baretton","year":"2019","journal-title":"Virchows Arch"},{"key":"B97","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"R\u00fcschoff","year":"2010","journal-title":"Virchows Arch"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800774","article-title":"Standardization of HER2 testing: results of an international proficiency-testing ring study","volume":"20","author":"Dowsett","year":"2007","journal-title":"Mod Pathol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1200\/JCO.2022.40.16_suppl.4572","article-title":"Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma 2022 ASCO annual meeting; 2022 jun 3-7; Chicago, IL, USA","volume":"2022","author":"Lei","year":"2022","journal-title":"J Clin Oncol"},{"key":"B100","first-page":"4572","article-title":"HER-2 is new again in bladder cancer. 2022 ASCO annual meeting; 2022 jun 3-7; Chicago, IL, USA","volume":"2022","author":"Galsky","year":"2022","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-200944","article-title":"Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression","volume":"66","author":"Chen","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2022.40.6_suppl.557","article-title":"Prognostic value of HER2 expression levels for upper tract urothelial carcinoma","volume":"2022","author":"Li","year":"2022","journal-title":"J clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.06.117","article-title":"Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract","volume":"66","author":"Tsai","year":"2005","journal-title":"Urology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1011885\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T07:21:21Z","timestamp":1666336881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1011885\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":105,"alternative-id":["10.3389\/fonc.2022.1011885"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1011885","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"article-number":"1011885"}}